Pfizer: raises full-year forecast
(CercleFinance.com) - Pfizer said its second-quarter net profit rose by 26%, helped by products such as the stroke drug Eliquis, as well as biosimilars and growth in emerging markets.
The U.S. drugmaker earned 3.8 billion dollars, or 65 cents per share, in the past quarter, up from 3 billion dollars, or 51 cents per share, a year ago.
Revenues rose by 5% to 13.5 billion dollars. The company slightly raised its full-year adjusted profit forecast to between 2.95 dollars and 3.05 dollars per share, from its previous estimate of 2.90 dollars to 3 dollars.
"I am pleased with our results over the first-half of 2018, which keep us on track to deliver a solid financial performance this year," said Frank D'Amelio, group chief financial officer.
However, Pfizer shares were down 0.5% in pre-market trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The U.S. drugmaker earned 3.8 billion dollars, or 65 cents per share, in the past quarter, up from 3 billion dollars, or 51 cents per share, a year ago.
Revenues rose by 5% to 13.5 billion dollars. The company slightly raised its full-year adjusted profit forecast to between 2.95 dollars and 3.05 dollars per share, from its previous estimate of 2.90 dollars to 3 dollars.
"I am pleased with our results over the first-half of 2018, which keep us on track to deliver a solid financial performance this year," said Frank D'Amelio, group chief financial officer.
However, Pfizer shares were down 0.5% in pre-market trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.